Company intelligence / Profile preview
EHL Bio Co., Ltd.
South Koreacosme-kotobuki.jp ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
EHL Bio has two main programs in clinical trials: an autologous mesenchymal stem cell therapy for severe atopic dermatitis in Phase 2, and autologous urine-derived stem cells for chronic kidney diseases in Phase 1.
- Therapeutic areas
- CardiovascularMetabolic DisordersRheumatologyNephrologyImmunologyDermatologyNeurology
- Modalities
- Stem cell therapyMesenchymal stem cell therapyImmune cell therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on EHL Bio Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EHL Bio Co., Ltd..